Dr. Melanie Franklin is a pediatric psychologist at Children's Hospital of Philadelphia with expertise in sleep disorders, treatment adherence, and pediatric psychology. She operates within the Department of Child and Adolescent Psychiatry and Behavioral Sciences and collaborates across multiple teams. BA in Psychology – Muhlenberg College PhD in School Psychology – Lehigh University Residency and Fellowship in Pediatric Psychology – Nemours/A.I. DuPont Children’s Hospital Her research focuses on: Sleep behavior in chronic illness populations Mental health communication barriers ADHD functional outcomes Treatment adherence strategies Recent publications demonstrate expertise in ADHD comorbidities , Cystic Fibrosis sleep interventions , and academic functioning analysis . Key collaborations include: Psychiatry and Behavioral Sciences Sleep Center Pulmonary and Sleep Medicine Division
Silvestro Micera is a Full Professor at the Swiss Federal Institute of Technology Lausanne (EPFL) and holds the Bertarelli Foundation Chair in Translational Neuroengineering. He directs the Translational Neural Engineering Laboratory and teaches courses including Neural signals and signal processing and Translational neuroengineering . His research bridges neural interfaces, robotics, and neuroprosthetics to restore motor functions in spinal cord injuries, stroke, and amputations. Micera's research integrates implantable neural interfaces, robotic rehabilitation, and hybrid neuro-prosthetic systems. Key focus areas include: Robotic neurorehabilitation for mobility restoration Neural control mechanisms in movement CNS/PNS neural interface development Bioelectronic modulation for sensory feedback His recent publications emphasize machine learning-driven motor recovery prediction, closed-loop sensory feedback systems, and minimally invasive neuroprosthetics. Trends include AI-optimized stimulation protocols, multimodal data fusion for rehabilitation, and clinical translation of neural bypass technologies. Awards: IEEE EMBS Early Career Achievement Award (2009) IEEE EMBS Technical Achievement Award (2021) Micera leads EU-funded projects such as TIME, CLONS, and NeuWalk, focusing on neural prostheses. He advises 8 current and 18 former PhD students in neuroengineering. His lab collaborates with MIT, Harvard, and industry partners (e.g., Plexon) to advance translational neurotechnologies.
Christopher M EARLS is a Professor in the Department of Psychology at Université de Montréal's Faculty of Arts and Sciences. He specializes in forensic psychology, psychopathology, and behavioral studies with a focus on sexual delinquency and juvenile prostitution. His research explores the intersections of psychopathy, criminal behavior, and mental health comorbidities. He teaches courses including Psychopathology: Introduction across undergraduate programs in psychology, social sciences, and cognitive neuroscience. His academic contributions span over two decades, with notable work on psychopathy assessment, parenting practices in non-criminal populations, and sexual behavior conditioning. Education Affiliations: Université de Montréal (primary) Teaching Programs: Baccalauréat en psychologie, Neuroscience cognitive, Social Work programs Dr. EARLS has directed 10+ theses and mémoires since 1998, focusing on forensic psychology topics like sexual delinquency correlates and psychopathy measurement validity. His work bridges clinical psychology with sociocultural factors, particularly in marginalized populations like sex workers and juvenile offenders. Research Highlights: Clinical assessment tools comparison (paper vs. digital psychopathy scales) Gender differences in psychopathy expression Impact of childhood trauma on sexual interest development Though no formal awards are listed, his extensive publication record reflects sustained contributions to forensic and clinical psychology research.
Allison Ross Eckard, MD is Professor in the Departments of Pediatrics and Medicine at the Medical University of South Carolina (MUSC) College of Medicine, serving as Division Chief for Pediatric Infectious Diseases and Director of MUSC's Ryan White Pediatric HIV Clinic and HIV Transition Clinic. She maintains an adjunct faculty position at Emory University and holds board certification in Pediatrics and Pediatric Infectious Diseases. Her primary research focuses on metabolic, cardiovascular, and nutritional complications of chronic HIV and antiretroviral therapy across age groups, with emphasis on inflammation's role in comorbidities like cardiovascular disease and bone disorders. Current investigations include NIH R01-funded research on interventions for weight gain and abdominal fat in HIV, vitamin D supplementation, and statin therapy. She has published nearly 60 peer-reviewed papers on HIV pathogenesis and treatment optimization. Dr. Eckard co-chairs the DHHS panel for Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Exposed and HIV-Infected Children and serves on the DHHS panel for Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV . Her clinical work specializes in comprehensive HIV care for children through young adults, with particular focus on adolescent/young adult transition issues and global health initiatives through Lespwa Timoun in Haiti. Recent efforts include developing COVID-19 treatment guidelines for children and school safety protocols. HIV Specialist certification (American Academy of HIV Medicine) Fellow, Infectious Diseases Society of America Fellow, Pediatric Infectious Diseases Society Fellow, HIV Medical Association Member, HIV Medical Association's 'Ending the HIV Epidemic' working group She leads MUSC's HIV education initiatives and serves as inpatient consultant for pediatric infectious diseases, with advanced training in tropical medicine. Her NIH-funded research examines targeted interventions to minimize comorbidity development in HIV, while her clinical leadership spans the Ryan White HIV program, transition clinics, and global health partnerships.
Karen Piper Hanley is Professor of Molecular Medicine and Head of Division in the Division of Diabetes, Endocrinology & Gastroenterology at the University of Manchester. She serves as the fibrosis lead in the Wellcome Trust Centre for Cell-Matrix Research and previously served as Director of Core Research Technologies (2019-2022). She is also an editorial board member for Scientific Reports. Her research focuses on fibrosis (scarring) mechanisms across multiple organs, particularly liver, kidney, and lung fibrosis. Her lab investigates the cellular and molecular basis of fibrotic disease, with emphasis on how pathological scar components are produced and how they signal to surrounding cells. Key areas include the role of SOX9 transcription factor, integrin beta-1 signaling, Group 1 PAKs, and YAP1 in fibrosis progression. Her recent publications reveal trends toward increased clinical translation of fibrosis research, with studies on health inequalities in liver cancer care, post-COVID diabetes incidence, and innovative approaches to liver disease detection. Her work increasingly integrates spatial transcriptomics and advanced omics technologies to understand cellular transitions in liver disease. Career-track postdoctoral fellowship from the University of Southampton (2006) As senior postgraduate tutor, she has mentored numerous PhD students who have presented at key conferences and authored high-quality manuscripts. All her PhD students have submitted and been awarded their degrees within 4 years. She has successfully guided previous Academic Clinical Fellows to win MRC clinical training fellowships. Her teaching extends to undergraduate Personal & Professional Development and supervision of MRes and BSc students, many of whom have achieved first-class degrees and prestigious awards. Her lab maintains active collaborations with Professor Neil Hanley's group on human development, stem cells, and regenerative medicine, bridging developmental biology with fibrosis research to understand why regeneration is impaired in chronic diseases.
Christopher Weidlich is an Assistant Professor of Clinical in the School of Nursing and Health Studies at the University of Miami. His academic focus includes psychiatric nursing, mental health education, and healthcare provider well-being. He is involved in research addressing simulation-based education, mental health disorders in occupational groups such as fire investigators, and interventions to improve resilience among healthcare providers. His research interests span simulation modalities in psychiatric nursing education, organizational stigma's impact on mental health service utilization, and substance abuse trends like xylazine adulteration. He has also contributed to studies on military healthcare, including resilience programs for providers and PEMF therapy for chronic pain. Dr. Weidlich’s work is supported by his affiliation with the University of Miami’s School of Nursing and Health Studies, leveraging resources such as the Simulation Hospital Advancing Research and Education (S.H.A.R.E.®) facility. His research emphasizes practical applications in clinical settings and improving patient outcomes through innovative educational and therapeutic approaches.
Dr. Rebecca Pratt is a tenured Professor in the Department of Foundational Medical Studies at Oakland University William Beaumont School of Medicine (OUWB), where she has been a faculty member since January 2018. She previously held professorial roles at Michigan State University College of Osteopathic Medicine (MSUCOM), where she taught anatomy, embryology, neuroanatomy, physiology, and histology, and served as Associate Professor and Director of Histology at the West Virginia School of Osteopathic Medicine. She also held appointments at Grand Valley State University and completed postdoctoral training at Purdue University. Ph.D., Cell Biology and Oncology, Purdue University B.S., Zoology and Botany/Plant Pathology, Michigan State University Dr. Pratt's research focuses on the fascial system and its role in whole-body health, including fascial continuity, muscle attachment, somatic pain transmission, and biochemical communication. She integrates radiology into anatomy education and advocates for evidence-based medical curricula. Her work bridges clinical anatomy, histology, embryology, and physiology with modern educational practices. Her recent publications reflect a strong emphasis on fascial anatomy, medical education innovation, and the integration of imaging in teaching. Themes include plastination, generational learning trends, and fascia’s role in women's health and athletic performance, published in journals like Clinical Anatomy and Anatomical Sciences Education , as well as in Women and Men’s Health and NIKE magazines. Scientific awards and honors include: Basmajian Award (American Association of Anatomy) Keith and Marion Moore Award (AAA) Five consecutive Golden Apple Teaching Awards at MSUCOM Golden Apple Award at OUWB Dr. Pratt has served in major leadership roles, including President of the International Fascia Research Society, Board Member of the American Association of Anatomy (AAA) and the American Association of Clinical Anatomy (AACA), and Chair of multiple AAA committees. She is a Visiting Anatomy Professor at Weill Cornell and St. George’s University School of Medicine, and faculty advisor for the Docapellas at OUWB. She has been an invited speaker internationally and contributed to high-impact projects like the BodyWorlds Fascial Net Plastination Project. She actively serves on OUWB’s Admissions and Student Promotion and Retention Committees. Dr. Pratt leads and organizes major international initiatives, including the Women's Clinical Health Summit in Rio de Janeiro (2024) and the Fascia Research Congress in New Orleans (2025), fostering global collaboration in fascial science. Her lab and research team focus on fascial anatomy and medical education, working closely with institutions in Italy (University of Padova) and Germany (BodyWorlds project).
Johan Gustav Bellika is a Professor at the Department of Clinical Medicine, UiT The Arctic University of Norway, based in Tromsø. His work bridges clinical medicine with health informatics, focusing on practical applications that improve healthcare delivery and patient outcomes. Current Position: Professor, Department of Clinical Medicine Institution: UiT The Arctic University of Norway Location: Tromsø, Norway Contact: johan.gustav.bellika@uit.no Professor Bellika's research spans several critical areas in modern healthcare. His primary focus is on health informatics with particular emphasis on medical data privacy, electronic health records, and the application of artificial intelligence in clinical settings. He has made significant contributions to understanding chronic pain management through technology, primary care research networks, and patient-centered care models. His work often involves large population studies such as the Tromsø Study, examining how digital health tools impact healthcare utilization and patient outcomes. His research demonstrates a consistent thread connecting technological innovation with practical clinical applications. Bellika has been instrumental in developing privacy-preserving architectures for healthcare data analysis, which enable researchers to gain insights from sensitive health information without compromising patient privacy. His work on federated learning frameworks represents cutting-edge approaches to analyzing medical data while maintaining strict privacy controls. Health Informatics and Medical Data Privacy Chronic Pain Management through Technology Primary Care Research Networks (PraksisNett) Electronic Health Records and Clinical Decision Support Patient-Centered Digital Health Solutions Federated Learning Applications in Healthcare Professor Bellika's publication record shows a strong trend toward interdisciplinary research that combines clinical medicine, computer science, and public health. His recent work increasingly focuses on the intersection of artificial intelligence and healthcare, particularly how machine learning can be applied to chronic conditions while maintaining rigorous privacy standards. The geographical scope of his research extends across Norway with particular emphasis on Northern Norwegian populations, providing valuable insights into healthcare delivery in Arctic and remote regions. His collaborative approach is evident through numerous co-authored publications with researchers across multiple institutions and disciplines. While specific awards aren't detailed in the available information, his extensive publication record in reputable journals suggests recognition within his field. Professor Bellika has been actively involved in several major research initiatives including the Tromsø Study and PraksisNett, Norway's nationwide practice-based research network. His work on privacy-preserving architectures for healthcare data has significant implications for how medical research can be conducted while respecting patient confidentiality. He appears to be particularly focused on translating research findings into practical tools for clinicians, as evidenced by his work on audit and feedback systems for antibiotic prescribing.
Weiping Tang is a Professor of Pharmaceutical Sciences and Chemistry at the University of Wisconsin-Madison, holding the Janis Apinis Professorship in the School of Pharmacy and the Vilas Distinguished Achievement Professorship. He also serves as Director of the Medicinal Chemistry Center at the School of Pharmacy and maintains a faculty appointment with the Department of Chemistry in the College of Letters and Science. Janis Apinis Professor of Pharmaceutical Sciences Vilas Distinguished Achievement Professor Director of Medicinal Chemistry Center Faculty Appointment with Department of Chemistry Dr. Tang received his B.S. in Chemistry from Peking University in 1997, M.S. in Chemistry from New York University in 1999, Ph.D. in Organic Chemistry from Stanford University in 2005, and completed a postdoctoral fellowship in Medicinal Chemistry, Chemical Biology and Drug Discovery at Harvard University in 2007. Dr. Tang's research program focuses on drug discovery for cancer, infectious diseases, and neurodegenerative disorders through three interconnected areas: Organic Synthesis (advancing glycoscience through novel carbohydrate synthesis technologies), Medicinal Chemistry (developing small molecules that selectively remove disease-associated proteins), and Chemical Biology (dissecting biological pathways using novel small molecule probes). His group operates as an interdisciplinary team where chemists and biologists collaborate closely on drug discovery projects, with particular emphasis on developing novel degraders for disease-causing proteins. Analysis of Dr. Tang's publication record reveals a significant shift toward targeted protein degradation technologies, particularly PROTACs and molecular glues, while maintaining strong foundations in carbohydrate chemistry. His most impactful recent work includes developing degraders for extracellular and membrane proteins (previously considered 'undruggable'), creating rapid synthesis platforms like Rapid-TAC and Rapid-Glue, and advancing understanding of ternary complex formation for novel PROTAC design. His research spans both chemical methodology development and therapeutic applications across multiple disease areas. Vilas Distinguished Achievement Professorship Janis Apinis Professorship Numerous high-impact publications in leading chemistry and pharmacology journals Editor's pick and hot paper designations for significant contributions Dr. Tang mentors a diverse team of graduate students, postdoctoral fellows, and staff scientists with expertise spanning synthetic chemistry, medicinal chemistry, carbohydrate chemistry, computational chemistry, biochemistry, and cell biology. His group has developed innovative platforms for the rapid synthesis of protein degraders and has made significant contributions to understanding the mechanisms of action for these novel therapeutics. Current research includes developing selective degraders for cancer targets like RIPK1, BRD4, and CARM1, as well as advancing delivery systems for clinical translation. The Tang Research Group maintains state-of-the-art facilities within the School of Pharmacy at UW-Madison, equipped for comprehensive chemical synthesis, compound characterization, and biological evaluation. The group actively collaborates with researchers across campus and with industry partners to advance discoveries toward clinical applications, with particular focus on cancer therapeutics and protein degradation technologies.
Wing Lam is an Associate Research Scientist in the Department of Pharmacology at the Yale School of Medicine. He holds a BSc in Molecular Biology and a PhD in Biochemical Pharmacology from City University of Hong Kong, followed by postdoctoral training at Yale. His research focuses on developing traditional Chinese medicine (TCM) formulations as adjuvants for cancer therapy, notably YIV-906, which enhances chemotherapy efficacy and mitigates intestinal toxicity. Lam also pioneered the STAR database for herbal drug discovery and the Mechanism-Based Quality Control (MBQC) platform for botanical drug standardization. Education: BSc (Hons) Molecular Biology, City University of Hong Kong, 1995 PhD Biochemical Pharmacology, City University of Hong Kong, 1999 Postdoc, Pharmacology, Yale University, 1999-2002 His research interests span cancer pharmacology, TCM modernization, and mitochondrial toxicity mechanisms. Key projects include YIV-906’s role in enhancing anti-PD1 and CAR T-cell therapies, developing L-nucleoside analogs like troxacitabine, and investigating tylophorine analogs’ antitumor effects. Lam has co-chaired sessions at multiple Consortium for Globalization of Chinese Medicine (CGCM) meetings and contributed to patents on herbal drug formulations and quality control methods. Recent work explores YIV-906’s potential for inflammatory bowel disease (IBD) and phase II clinical trials for colon and liver cancers. Lam’s publications highlight synergistic drug interactions, mitochondrial DNA depletion mechanisms, and TCM’s evidence-based application in chronic diseases. His grants include studies on PHY906 as an adjuvant in rectal cancer therapy and collaborations with Yiviva, Inc. He maintains active roles in editorial boards, including a special issue on herbal drug quality control in Frontiers in Pharmacology . Lam’s lab is embedded within Dr. Yung-Chi Cheng’s group, focusing on translational pharmacology and botanical drug innovation.
Kora DeBeck is a Distinguished Professor of Substance Use and Drug Policy in the School of Public Policy at Simon Fraser University, a CIHR Applied Public Health Chair, and Dorothy Killam Fellow. She is also a Research Scientist with the BC Centre on Substance Use and Principal Investigator of the At-Risk Youth Study (ARYS), a longitudinal cohort tracking over 1,200 street-involved youth. Her research focuses on substance use policy, health services for marginalized populations, and the structural drivers of drug-related harms. She has published over 200 peer-reviewed articles challenging ineffective drug enforcement models and advocating for policy reforms. Recent publications analyze trends in opioid use, harm reduction during the COVID-19 pandemic, drug decriminalization, and youth-focused interventions. Her work consistently addresses social inequities through data-driven approaches to the toxic drug crisis. CIHR Applied Public Health Chair Dorothy Killam Fellow Michael Smith Health Research BC Scholar Award Distinguished SFU Professorship She has secured over $50 million in research funding, including $21M as principal investigator for ARYS. Her lab collaborates with healthcare providers, community organizations, and policymakers to translate research into practice.
Ashli Owen-Smith is a behavioral scientist affiliated with the School of Public Health at Georgia State University , where her research focuses on mental health disparities, suicide prevention, and integrative/complementary approaches for complex mental-physical health conditions. She works with underserved populations including refugees/immigrants, incarcerated individuals, and LGBTQ+ communities through community-based participatory research and mixed-methods frameworks. Her current projects are funded by CDC , DBHDD , and DPH . Education: Ph.D. in Behavioral Sciences (Emory, 2009), S.M. in Public Health (Harvard, 2005), B.A. in Psychology (Smith College, 2001) Her research spans mental health , trauma , suicide prevention , and mindfulness-based interventions . Recent work examines telehealth adaptations for chronic pain and mental health, vaccine hesitancy in refugee communities, and social determinants of suicide . She leads studies on gender-affirming care and health disparities in LGBTQ+ populations. Key article trends include epidemiological analysis of suicide risk factors, COVID-19 impacts on mental health, ICD-10 coding for autism, and complementary medicine in trauma recovery. Subfields span telehealth , health equity , mental-physical comorbidity , and community engagement . Students she has mentored include C.A. Scarlett , T. Griner , and M.M. Sesay . Her work integrates public health policy , clinical research , and health systems analysis .
Dr. Ian Yi Han is an Assistant Professor at the Saw Swee Hock School of Public Health, National University of Singapore (NUS), and Co-Director of the Center for Health Intervention and Policy Evaluation Research (HIPER). His research focuses on evaluating community-based health interventions, telehealth programs, and the impact of built environments on health behaviors. He holds a Ph.D. in Behavioral Nutrition from Columbia University, an M.A. in Psychology in Education, and a B.Sc. in Neural Science & Psychology from New York University. Key research areas include programme evaluation, population health, health services research, and dietary behaviors. He explores how interventions can improve patient experiences and population health outcomes, particularly through telemedicine and lifestyle modifications. His work has been published in journals like npj Digital Medicine, Metabolism, and the Journal of Nutrition Education and Behavior. Notable projects include studies on blood pressure telemonitoring, diabetes management during the pandemic, and supermarket intervention strategies for obesity prevention. Dr. Han has contributed to policy initiatives through roles such as Senior Research Fellow at the National University Health System and Lecturer at Columbia University. He advises on primary care research and collaborates on global health projects, emphasizing interdisciplinary solutions to public health challenges.
Dr. Susan Hua is an Associate Professor at the University of Newcastle's School of Biomedical Sciences and Pharmacy, specializing in translational nanopharmaceutics and therapeutic targeting. She established the first translational nanopharmaceutics laboratory in the Hunter region, focusing on drug delivery systems for gastrointestinal, musculoskeletal, and reproductive pathologies. Education: Bachelor of Pharmacy with Honours, University of Queensland (UQ) PhD in Neuroscience and Nanotechnology, UQ Research Interests: Her work centers on using nanotechnology to create targeted drug delivery systems for diseases such as chronic pain, inflammatory conditions, and obstetric complications. Key focuses include oxytocin receptor-targeted liposomes for uterine therapies and localized drug delivery to bypass biological barriers. Awards & Recognition: 2020 DVC(A) Educator Innovation Award 2017 NSW Premier's Early Career Researcher of the Year 2015 HMRI Early Career Researcher of the Year Grants & Collaborations: A/Prof Hua has secured over $5.5M in grants, including NHMRC and ARC funding. She collaborates with institutions like HMRI, John Hunter Hospital, and global teams on projects like nanoparticle-based treatments for preterm labor and uterine hemorrhage. Teaching & Leadership: She coordinates pharmacy programs, emphasizing clinical application and innovation. Her courses include Pharmacotherapeutics and Pharmacy Practice, with awards for teaching excellence (2020, 2011). Labs & Programs: Head of Therapeutic Targeting Program, University of Newcastle Director, Translational Pharmaceutics & Medical Technologies Theme (HMRI)
Dr. Frank Rudzicz is an Associate Professor in the Faculty of Computer Science at Dalhousie University. His research lies at the intersection of artificial intelligence, natural language processing, and healthcare, with a focus on developing machine learning systems that improve clinical decision-making, patient outcomes, and accessibility in medicine. He holds a BSc from Concordia University (2004), an MEng from McGill University (2006), and a PhD from the University of Toronto (2011). His research interests include Natural Language Processing, Machine Learning, Healthcare, Speech Technologies, Explainable AI, and Fairness in ML. Dr. Rudzicz's recent publications span a wide range of topics, including Alzheimer's detection through speech analysis, surgical outcome prediction, mental health monitoring, privacy in AI, and the application of large language models in clinical settings. His work consistently emphasizes ethical AI, patient privacy, and real-world clinical integration. He has received several awards, including a Best Paper award at EMNLP 2020, a Best Student Paper award at ICASSP 2021, and the ISCA Best Student Paper award in 2013. His research has been published in top-tier journals such as Nature Scientific Reports , JAMA Network Open , IEEE Access , and Frontiers in Human Neuroscience , as well as leading conferences including NeurIPS, ACL, ICML, and Interspeech. Dr. Rudzicz supervises a dynamic research group working on AI for health, with active projects in voice-based diagnostics, ambient clinical documentation, explainable AI for surgery, and wearable-based monitoring for chronic diseases. He collaborates widely across disciplines, including with clinicians, neuroscientists, ethicists, and public health experts. He is also involved in major initiatives such as the Genetics Navigator study and Bridge2AI-Voice, aiming to build ethically sourced, diverse biomedical datasets. His lab actively explores the societal implications of AI in healthcare, including fairness, trust, and resistance to malicious fine-tuning.
